// App-Quantinova.ai

EP977 : COMPARISON OF OUTCOMES WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-1 VERSUS STANDARD OF CARE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS IN CLINICAL TRIALS OF DARATUMUMAB

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Thomas Martin

  • Amrita Krishnan

  • Sundar Jagannath

  • Keqin Qi

  • Anil Londhe

  • Maneesha Mehra

  • Sandhya Nair

  • Joris Diels

  • Martin Vogel

  • Jordan M. Schecter

  • Arnob Banerjee

  • Satish Valluri

  • Jesus G. Berdeja

  • Tonia Nesheiwat

  • Ashraf Garrett

  • Saad Z. Usmani

  • Kwee Yong

Medical Centers

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen R&amp

  • D,Yardley,United States

  • Titusville, NJ, United States

  • Legend Biotech USA,Piscataway, NJ,United States

  • Mount Sinai Medical Center, New York, United States

  • Sarah Cannon Research Institute, Nashville,United States

  • Janssen Global Services, Raritan, NJ, United States

  • Kings College London, London, United Kingdom

  • D,Raritan,United States

  • Levine Cancer Institute/Atrium Health,Charlotte,Verenigde Staten

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, La Verne, CA

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • D,Spring House,United States

Locations

  • Belgium

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • NCT03548207

  • NCT02076009

  • NCT02136134

  • NCT01998971

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved